Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.59
OTCPK:TEVJF's Cash to Debt is ranked lower than
71% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. OTCPK:TEVJF: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:TEVJF' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.33 Max: N/A
Current: 0.59
Equity to Asset 0.55
OTCPK:TEVJF's Equity to Asset is ranked lower than
62% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OTCPK:TEVJF: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:TEVJF' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.55
0.39
0.6
Interest Coverage 7.91
OTCPK:TEVJF's Interest Coverage is ranked lower than
69% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.86 vs. OTCPK:TEVJF: 7.91 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TEVJF' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.22 Max: N/A
Current: 7.91
F-Score: 6
Z-Score: 2.10
M-Score: -2.88
WACC vs ROIC
4.51%
3.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.10
OTCPK:TEVJF's Operating margin (%) is ranked higher than
62% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. OTCPK:TEVJF: 12.10 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:TEVJF' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 12.1
8.12
25.46
Net-margin (%) 9.13
OTCPK:TEVJF's Net-margin (%) is ranked higher than
62% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.02 vs. OTCPK:TEVJF: 9.13 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:TEVJF' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 12.03 Max: 20.75
Current: 9.13
5.73
20.75
ROE (%) 6.60
OTCPK:TEVJF's ROE (%) is ranked lower than
52% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. OTCPK:TEVJF: 6.60 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:TEVJF' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 10.00 Max: 16.18
Current: 6.6
4.23
16.18
ROA (%) 3.48
OTCPK:TEVJF's ROA (%) is ranked lower than
51% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. OTCPK:TEVJF: 3.48 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:TEVJF' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 4.98 Max: 9.34
Current: 3.48
2.26
9.34
ROC (Joel Greenblatt) (%) 33.29
OTCPK:TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.79 vs. OTCPK:TEVJF: 33.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:TEVJF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.41  Med: 33.40 Max: 49.79
Current: 33.29
16.41
49.79
Revenue Growth (3Y)(%) -0.80
OTCPK:TEVJF's Revenue Growth (3Y)(%) is ranked lower than
69% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OTCPK:TEVJF: -0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:TEVJF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 15.60 Max: 23.4
Current: -0.8
-0.8
23.4
EBITDA Growth (3Y)(%) 6.60
OTCPK:TEVJF's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. OTCPK:TEVJF: 6.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:TEVJF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 14.80 Max: 47.3
Current: 6.6
-10.5
47.3
EPS Growth (3Y)(%) -6.80
OTCPK:TEVJF's EPS Growth (3Y)(%) is ranked lower than
69% of the 509 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. OTCPK:TEVJF: -6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:TEVJF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.5  Med: 15.40 Max: 69.6
Current: -6.8
-25.5
69.6
» OTCPK:TEVJF's 10-Y Financials

Financials (Next Earnings Date: 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF839.504.367 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:SGIOF, OTCPK:ESALY, NYSE:PRGO, OTCPK:MKGAY, OTCPK:APNHY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HKMPF, OTCPK:HLUYY, NYSE:VRX, OTCPK:MDABY, NYSE:MNK, NYSE:TARO, OTCPK:SFOSF, OTCPK:HYPMY, OTCPK:DNPUF » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Its other activities include the over-the-counter ("OTC") medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is mainly conducted through a joint venture with P&G, which combines Company's production capabilities and market reach with P&G's marketing expertise and expansive platform. It has market presence in the United States, Europe and other markets. The Generic medicines include chemical and therapeutic equivalents of originator medicines in dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty medicines include several franchises in the core therapeutic areas of CNS medicines such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines such as ProAir HFA and QVAR. It also includes other therapeutic areas, such as oncology medicines, including Treanda, women's health and selected other areas. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Ratios

vs
industry
vs
history
P/E(ttm) 25.05
TEVJF's P/E(ttm) is ranked higher than
54% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.34 vs. TEVJF: 25.05 )
Ranked among companies with meaningful P/E(ttm) only.
TEVJF' s P/E(ttm) Range Over the Past 10 Years
Min: 10.49  Med: 20.33 Max: 938.25
Current: 25.05
10.49
938.25
PE(NRI) 25.05
TEVJF's PE(NRI) is ranked higher than
53% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.24 vs. TEVJF: 25.05 )
Ranked among companies with meaningful PE(NRI) only.
TEVJF' s PE(NRI) Range Over the Past 10 Years
Min: 10.53  Med: 20.57 Max: 1876.5
Current: 25.05
10.53
1876.5
Price/Owner Earnings (ttm) 14.14
TEVJF's Price/Owner Earnings (ttm) is ranked higher than
81% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.00 vs. TEVJF: 14.14 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TEVJF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.02  Med: 18.03 Max: 67.1
Current: 14.14
9.02
67.1
P/B 1.64
TEVJF's P/B is ranked higher than
69% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. TEVJF: 1.64 )
Ranked among companies with meaningful P/B only.
TEVJF' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 2.25 Max: 4.81
Current: 1.64
1.36
4.81
P/S 2.18
TEVJF's P/S is ranked higher than
55% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. TEVJF: 2.18 )
Ranked among companies with meaningful P/S only.
TEVJF' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 2.96 Max: 5.83
Current: 2.18
1.58
5.83
PFCF 8.81
TEVJF's PFCF is ranked higher than
84% of the 189 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.95 vs. TEVJF: 8.81 )
Ranked among companies with meaningful PFCF only.
TEVJF' s PFCF Range Over the Past 10 Years
Min: 8.46  Med: 17.90 Max: 97.63
Current: 8.81
8.46
97.63
POCF 7.60
TEVJF's POCF is ranked higher than
83% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.49 vs. TEVJF: 7.60 )
Ranked among companies with meaningful POCF only.
TEVJF' s POCF Range Over the Past 10 Years
Min: 6.58  Med: 11.77 Max: 23.41
Current: 7.6
6.58
23.41
EV-to-EBIT 22.27
TEVJF's EV-to-EBIT is ranked lower than
57% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. TEVJF: 22.27 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 20.90 Max: 991
Current: 22.27
11.4
991
EV-to-EBITDA 14.45
TEVJF's EV-to-EBITDA is ranked higher than
56% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.28 vs. TEVJF: 14.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9  Med: 16.60 Max: 290.6
Current: 14.45
9
290.6
PEG 10.36
TEVJF's PEG is ranked lower than
90% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. TEVJF: 10.36 )
Ranked among companies with meaningful PEG only.
TEVJF' s PEG Range Over the Past 10 Years
Min: 0.32  Med: 1.10 Max: 238.44
Current: 10.36
0.32
238.44
Shiller P/E 18.90
TEVJF's Shiller P/E is ranked higher than
81% of the 149 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.12 vs. TEVJF: 18.90 )
Ranked among companies with meaningful Shiller P/E only.
TEVJF' s Shiller P/E Range Over the Past 10 Years
Min: 18.53  Med: 29.47 Max: 73.59
Current: 18.9
18.53
73.59
Current Ratio 1.32
TEVJF's Current Ratio is ranked lower than
79% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVJF: 1.32 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 1.32
0.92
2.95
Quick Ratio 1.01
TEVJF's Quick Ratio is ranked lower than
75% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. TEVJF: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.08 Max: 2.19
Current: 1.01
0.63
2.19
Days Inventory 182.49
TEVJF's Days Inventory is ranked lower than
78% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.06 vs. TEVJF: 182.49 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 182.49
131.65
208.14
Days Sales Outstanding 97.21
TEVJF's Days Sales Outstanding is ranked lower than
66% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.75 vs. TEVJF: 97.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 97.21
95.91
153.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.87
TEVJF's Price/Projected FCF is ranked higher than
86% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. TEVJF: 0.87 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVJF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.51 Max: 29.19
Current: 0.87
0.65
29.19
Price/DCF (Earnings Based) 1.98
TEVJF's Price/DCF (Earnings Based) is ranked lower than
72% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. TEVJF: 1.98 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.75
TEVJF's Price/Median PS Value is ranked higher than
80% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. TEVJF: 0.75 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVJF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.14 Max: 2.01
Current: 0.75
0.54
2.01
Earnings Yield (Greenblatt) (%) 4.49
TEVJF's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVJF: 4.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVJF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 4.80 Max: 8.8
Current: 4.49
0.1
8.8
Forward Rate of Return (Yacktman) (%) -1.36
TEVJF's Forward Rate of Return (Yacktman) (%) is ranked lower than
67% of the 326 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.89 vs. TEVJF: -1.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVJF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 22.00 Max: 43.7
Current: -1.36
-5.7
43.7

More Statistics

Revenue (TTM) (Mil) $19,480
EPS (TTM) $ 1.93
Beta-0.27
Short Percentage of Float0.00%
52-Week Range $57.25 - 69.24
Shares Outstanding (Mil)914.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22,513 24,765 25,568
EPS ($) 5.26 6.00 6.46
EPS w/o NRI ($) 5.26 6.00 6.46
EPS Growth Rate
(3Y to 5Y Estimate)
7.40%
» More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Stocks Near 52-Week Lows May 26 2016 
John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Time To Buy Allergan Apr 06 2016 
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 
Polaris Global Value Fund Annual Letter 2015 Mar 21 2016 

More From Other Websites
Valeant Pharmaceuticals: Now You Downgrade It? Jun 23 2016
Teva, AstraZeneca settle patent dispute over multimillion-dollar drug Jun 23 2016
Blue Chips Dominate Jefferies Value Stocks to Buy Jun 23 2016
Impax Buys Mystery Generics Portfolio From Teva, Allergan Jun 21 2016
Impax Buying Teva, Allergan Drugs, Clearing Way For Deal Closing Jun 21 2016
Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal Jun 21 2016
$586M deal: Impax buying generic drugs FTC asked Teva and Allergan to sell Jun 21 2016
Why CarMax, Teva Pharmaceuticals And Three Other Stocks Are in Spotlight on Tuesday Jun 21 2016
With Acquisitions, Will Impax Become the Next Great Generic Drug Seller? Jun 21 2016
Eagle Pharma Downgraded On 'Challenging' Hospital Environment Jun 20 2016
Weekly Biotech Report Covering Epizyme Inc (EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd.... Jun 20 2016
[$$] Allergan, Teva Set to See Catalysts Jun 15 2016
Teva's Suspension of Marketing for Zecuity Product is Likely to Have Little Impact Jun 15 2016
Mesoblast shares tank after Teva exit Jun 14 2016
Mesoblast shares drop on outlook concerns Jun 13 2016
Mesoblast regains full rights to stem cell heart failure treatment Jun 13 2016
Allergan (AGN) Stock Advances After Dr. Reddy's Deal Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)